Episode
Episode 150: Myeloma Series, Pt. 10 - Role of CAR T for relapsed/refractory multiple myeloma (2026)
- Published
- Apr 1, 2026
- Processing state
not_requested- Canonical source
- https://www.thefellowoncall.com/tfocpodcast/myelomacart
Actions
POST https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-150-myeloma-series-pt-10-role-of-car-t-for-relapsed-refractory-multiple-myeloma-2026/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-150-myeloma-series-pt-10-role-of-car-t-for-relapsed-refractory-multiple-myeloma-2026.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this week’s episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next episode, we will continue on with a discussion on bispecific agents! This is a conversation that is so important in the current treatment landscape and one that you don’t want to miss. Content: - What are treatment options for patients with relapsed/refractory multiple myeloma (R/R MM)? - What is CAR T therapy? And what role does it play in R/R MM? - What are the available options for CAR T for R/R MM? - What are the toxicity profiles of available agents? - How to choose between the options? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast ! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube